Wolfe Research lifts Guardant Health to Outperform, sees 30% upside
PositiveFinancial Markets

Wolfe Research has upgraded Guardant Health to an 'Outperform' rating, suggesting a potential upside of 30% for investors. This positive outlook is significant as it reflects confidence in the company's growth prospects and its innovative approach in the healthcare sector, particularly in cancer detection and treatment. Such endorsements can influence market perception and attract more investors, potentially boosting the company's stock performance.
— Curated by the World Pulse Now AI Editorial System